Status:

UNKNOWN

Evaluation of Treatment Effect of Minimally Invasive Spinal Fusion Surgery

Lead Sponsor:

Chi Mei Medical Hospital

Conditions:

Spinal Fusion

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Participants with lumbar spondylosis, degenerative disc disease, spondylolisthesis, scoliosis, or trauma undergoing elective Transforaminal lumbar interbody fusion (TLIF) were recruited. The follow-up...

Detailed Description

After receiving prophylactic antibiotics according to the local hospital protocol, the patients were generally anesthetized in a prone position. Paramedian or midline posterior sections were conducted...

Eligibility Criteria

Inclusion

  • spinal fusion procedures in skeletally mature patients with Degenerative Disc Disease (DDD) at one or two contiguous levels from L2 to S1. DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These DDD patients may also have up to Grade I spondylolisthesis or retrolisthesis at the involved levels. Patients should have had six months of non-operative treatment prior to treatment with an intervertebral body fusion device.

Exclusion

  • Patients unsuitable for anesthesia
  • Active systemic infection, infection or suspected latent infection localized to the site of the proposed implantation
  • Excessive local inflammation
  • Rapid joint disease, bone absorption, osteopenia
  • Severe osteoporosis or osteopenia
  • Morbid obesity
  • Pregnancy
  • Open wounds
  • Patients have demonstrated allergy or foreign body sensitivity to any of the implant materials
  • Any medical or surgical condition which would preclude the potential benefit of spinal implant surgery, surgery, such as the presence of tumors, congenital abnormalities, elevation of sedimentation rate unexplained by other diseases, elevation of white blood cell count (WBC), or marked left shift in the WBC differential count
  • Patients whose activity, mental capacity, mental illness, alcoholism, drug abuse, occupation, or lifestyle may interfere with their ability to follow postoperative restrictions and who may place undue stresses on the implant during bony healing and may be at a higher risk of implant failure
  • Any patient in which implant utilization would interfere with anatomical structures or expected physiological performance
  • Any condition not described in the indications for use

Key Trial Info

Start Date :

March 25 2015

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 26 2023

Estimated Enrollment :

73 Patients enrolled

Trial Details

Trial ID

NCT05190055

Start Date

March 25 2015

End Date

February 26 2023

Last Update

July 19 2022

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.